Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Update

Autolus Therapeutics plc (NASDAQ:AUTL) was the recipient of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 10,730,000 shares, a drop of 6.1% from the August 31st total of 11,430,000 shares. Based on an average trading volume of 971,000 shares, the days-to-cover ratio is currently 11.1 days.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Avoro Capital Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 1st quarter worth about $78,765,000. Armistice Capital LLC boosted its holdings in shares of Autolus Therapeutics by 33.8% during the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock worth $21,750,000 after buying an additional 1,578,000 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Autolus Therapeutics by 82.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after buying an additional 2,487,778 shares during the period. Affinity Asset Advisors LLC boosted its holdings in shares of Autolus Therapeutics by 27.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock worth $14,964,000 after buying an additional 925,000 shares during the period. Finally, Great Point Partners LLC boosted its holdings in shares of Autolus Therapeutics by 195.0% during the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock worth $11,977,000 after buying an additional 2,275,000 shares during the period. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Stock Up 4.3 %

Shares of AUTL stock opened at $3.63 on Monday. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09. Autolus Therapeutics has a 1 year low of $2.01 and a 1 year high of $7.45. The firm’s fifty day moving average price is $4.00 and its two-hundred day moving average price is $4.32. The firm has a market capitalization of $965.71 million, a P/E ratio of -3.03 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, equities analysts predict that Autolus Therapeutics will post -0.84 EPS for the current fiscal year.

Analyst Ratings Changes

AUTL has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a research note on Monday, June 17th. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a research note on Monday, June 3rd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $8.70.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.